Transgenic mammals having human Ig loci including plural Vh and Vk regions and antibodies produced therefrom
First Claim
1. A transgenic non-human mammal having a genome, the genome comprising modifications, the modifications comprising:
- an inactivated endogenous immunoglobulin (Ig) locus, such that the mammal would not display normal B-cell development;
an inserted human heavy chain Ig locus in substantially germline configuration, the human heavy chain Ig locus comprising a human mu constant region and regulatory and switch sequences thereto, a plurality of human JH genes, a plurality of human DH genes, and a plurality of human VH genes; and
an inserted human kappa light chain Ig locus in substantially germline configuration, the human kappa light chain Ig locus comprising a human kappa constant region, a plurality of Jκ
genes, and a plurality of Vκ
genes, wherein the number of VH and Vκ
genes inserted are selected to substantially restore normal B-cell development in the mammal.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (VH and Vκ) gene regions. Advantageously, the inclusion of plural variable region genes enhances the specificity and diversity of human antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development to the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.
-
Citations
28 Claims
-
1. A transgenic non-human mammal having a genome, the genome comprising modifications, the modifications comprising:
-
an inactivated endogenous immunoglobulin (Ig) locus, such that the mammal would not display normal B-cell development;
an inserted human heavy chain Ig locus in substantially germline configuration, the human heavy chain Ig locus comprising a human mu constant region and regulatory and switch sequences thereto, a plurality of human JH genes, a plurality of human DH genes, and a plurality of human VH genes; and
an inserted human kappa light chain Ig locus in substantially germline configuration, the human kappa light chain Ig locus comprising a human kappa constant region, a plurality of Jκ
genes, and a plurality of Vκ
genes,wherein the number of VH and Vκ
genes inserted are selected to substantially restore normal B-cell development in the mammal. - View Dependent Claims (2, 3, 4, 5, 6, 7, 16)
-
-
8. In a transgenic non-human mammal having a genome that comprises modifications, the modifications rendering the mammal capable of producing human immunoglobulin molecules but substantially incapable of producing functional endogenous antibody molecules, the improvement comprising:
insertion into the genome of the mammal of sufficient human VH, DH, JH, Vκ
, and Jκ
genes such that the mammal is capable encoding greater than about 1×
106 different functional human immunoglobulin sequence combinations, without accounting for junctional diversity or somatic mutation events.
-
9. In a transgenic non-human mammal having a genome that comprises modifications, the modifications rendering the mammal capable of producing human immunoglobulin molecules but substantially incapable of producing functional endogenous antibody molecules, which modifications, with respect to the mammal'"'"'s incapacity to produce functional endogenous antibody molecules would not allow the mammal to display normal B-cell development, the improvement comprising:
insertion into the genome of the mammal of sufficient human VH, DH, JH, Vκ
, and Jκ
genes such that the mammal is capable of encoding greater than about 1×
106 different functional human immunoglobulin sequence combinations and sufficient VH and Vκ
genes to substantially restore normal B-cell development in the mammal.- View Dependent Claims (10)
-
11. A transgenic non-human mammal having a genome, the genome comprising modifications, the modifications comprising:
-
an inactivated endogenous heavy chain immunoglobulin (Ig) locus;
an inactivated endogenous kappa light chain Ig locus;
an inserted human heavy chain Ig locus, the human heavy chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yH2; and
an inserted human kappa light chain Ig locus, the human kappa light chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yK2. - View Dependent Claims (17, 18, 19, 20, 25)
-
-
12. A transgenic non-human mammal having a genome, the genome comprising modifications, the modifications comprising:
-
an inactivated endogenous heavy chain immunoglobulin (Ig) locus;
an inserted human heavy chain Ig locus, the human heavy chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yH2; and
an inserted human kappa light chain Ig locus, the human kappa light chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yK2. - View Dependent Claims (21)
-
-
13. A transgenic non-human mammal having a genome, the genome comprising modifications, the modifications comprising:
-
an inactivated endogenous heavy chain immunoglobulin (Ig) locus;
an inactivated endogenous kappa light chain Ig locus;
an inserted human heavy chain Ig locus, the human heavy chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yH2 without the presence of a human gamma-2 constant region; and
an inserted human kappa light chain Ig locus, the human kappa light chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yK2. - View Dependent Claims (22)
-
-
14. A transgenic non-human mammal having a genome, the genome comprising modifications, the modifications comprising:
-
an inactivated endogenous heavy chain immunoglobulin (Ig) locus;
an inactivated endogenous kappa light chain Ig locus;
an inserted human heavy chain Ig locus, the human heavy chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yH2 without the presence of a human gamma-2 constant region; and
an inserted human kappa light chain Ig locus, the human kappa light chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yK2. - View Dependent Claims (23)
-
-
15. A transgenic non-human mammal having a genome, the genome comprising modifications, the modifications comprising:
-
an inactivated endogenous heavy chain immunoglobulin (Ig) locus;
an inserted human heavy chain Ig locus, the human heavy chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yH2 without the presence of a human gamma-2 constant region; and
an inserted human kappa light chain Ig locus, the human kappa light chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yK2.
-
-
24. In a method for the production of transgenic mice, the transgenic mice having a genome, the genome comprising modifications, the modifications comprising insertion of a plurality of human variable regions, the improvement comprising:
insertion of the human variable regions from a yeast artificial chromosome.
-
26. In a transgenic mammal, the transgenic mammal comprising a genome, the genome comprising modifications, the modifications comprising an inserted human heavy chain immunoglobulin transgene, the improvement comprising:
the transgene comprising selected sets of human variable region genes that enable human-like junctional diversity and human-like complementarity determining region 3 (CDR3) lengths. - View Dependent Claims (27, 28)
Specification